Rare Neurodegenerative Disease Treatment Market
Global Rare Neurodegenerative Disease Treatment Market Size, Share & Trends Analysis Report by Indications (Parkinson’s Disease, Amyotrophic Lateral Sclerosis, Alzheimer’s Disease, Multiple Sclerosis, Spinal Muscular Atrophy, Huntington Disease, and Other Indications), by Drug Class (Immunomodulator Drugs, Cholinesterase Inhibitors, Dopamine Agonists, N-methyl-D-Aspartate Receptor Antagonists, and Others) Forecast 2022-2028 Update Available - Forecast 2024-2030
The global rare neurodegenerative disease treatment market is anticipated to grow at a significant CAGR of 6.8% during the forecast period. Neurodegenerative disease generally occurs when the nerve cells in the brain lose their functions and day by day die. Some of the physical and mental symptoms of this disease can be helped through treatment, but there are several ways to slow the disease progression. The risk of this disease generally increases with age. Research says that this disease develops by the combination of a person’s genes and the environment contributes to increasing the chances of this disease. The environmental factors can be pesticides, Fungicides, and insecticides. Some metals like Arsenic, manganese, and lead can also be a factor to develop neurodegenerative disease. Chemicals used in factories, Air pollution, and changing lifestyle are some of the factors boosting the chance of rare neurodegenerative disease. These nerve diseases affect people's body activities such as talking, breathing, and heart functions. Sometimes these diseases are genetic. Increasing awareness about this disease along with advanced treatment will propel the market growth during the forecast period.
Impact of COVID-19 Pandemic on Global Rare Neurodegenerative Disease Treatment Market
COVID-19 has already produced a great impact on the global health system. Mostly, the neurodegenerative disease affects the elder population. This occurs due to neuron loss in the brain as it is observed initially by memory declination. Mostly these patients need long-term care. In COVID-19 cases, 80% of deaths were in long-term care, people with low immunity, and respiratory diseases. Thus, neurogenerative patients had more risk of COVID-19 infection. The pandemic had increased the stress for the neurodegenerative patients, which resulted in anxiety, depression, hypoxia, a sleep disorder that was already one of the important factors of neurodegenerative deaths.
Segmental Outlook
The global rare neurodegenerative disease treatment market is segmented based on the indication and drug class. Based on the indications, the market is segmented into parkinson’s Disease, amyotrophic lateral sclerosis, alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, huntington disease, and other indications. Based on the drug class, the market is sub-segmented into immunomodulator drugs, cholinesterase inhibitors, dopamine agonists, N-methyl-D-aspartate receptor antagonists, Others . The above-mentioned segments can be customized as per the client's requirements and choices.
Global Rare Neurodegenerative Disease Treatment Market Share by Indications, 2022 (%)
The Alzheimer’s disease is anticipated to Hold a Prominent Share in the Global Rare Neurodegenerative Disease Treatment Market
Alzheimer’s disease is anticipated to hold the largest share in the market as 65% of the people are suffering from Alzheimer’s disease globally. According to the report by National Institute of Environmental Health Sciences of the US government, the Alzheimer’s Disease Association estimated that the number of Americans with this disease is around 6.2 million.The main cause of Alzheimer’s disease is the abnormal build-up of proteins in and around the brain cell. The most common protein involved is amyloid, which forms plaques around the brain cell. Several other factors which cause Alzheimer’s disease include age, genetic disorder, down syndrome, head injury, and cardiovascular disease. Among all these, age is the most significant factor. According to the Centres for Disease Control and Prevention of the US government, the prevalence of Alzheimer’s disease doubles up in every 5 years. Sometimes, the genes inherited by any individual by their parents also contribute to the risk of developing Alzheimer’s disease. Cardiovascular disease like obesity, smoking, diabetics, high blood pressure plays an important role in the increased chances of Alzheimer’s disease.
Regional Outlooks
The global rare neurodegenerative disease treatment Market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for particular region or country level as per the requirement. The North- America Rare Neurodegenerative disease treatment market is expected to hold prominent market share as the most number of Neurogenerative disease occurs in the North American region.
Global Rare Neurodegenerative Disease Treatment Market Growth, by Region 2022-2028
The North American Region is Estimated to Hold the Major Share in the Global Rare Neurodegenerative Disease Treatment Market
North America is anticipated to hold a prominent share is due to increased awareness in society. According to US National Library of Medicine National Institute of Health, it has been calculated that more than one million people are diagnosed with Parkinson’s neurogenerative disease . Moreover, North America is expected to hold the major share in the global market because of the presence of a larger number of drug manufacturing companies like Johnson & Johnson Services Inc., Pfizer Inc., Merck & Co. Inc., and AbbVie Inc.. They are in the process of continuous research and development for more innovations of drugs that they can launch to cure the disease neurodegenerative. All the major players of the drug manufacturing company of North America are involved in strategic alliances like acquisitions, partnerships, and collaboration along with research and development to launch new products to hold their position in the global market.
Market Players Outlook
The major companies serving the global rare neurodegenerative disease treatment market include Allergan plc. , Bayer AG, GlaxoSmithKline plc. , Johnson & Johnson Services Inc., Merck & Co. Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches to treat the disease, to stay competitive in the market. For instance, in 2019, Biogen had a strategic partnership with F. Hoffmann – La Roche Ltd. to ensure robust distribution of drugs and launched two new drugs named Madopar and Ocruves.
The Report Covers
- Market value data analysis of 2022 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global rare neurodegenerative disease treatment Market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on The Global Rare Neurodegenerative Disease Treatment Market
• Recovery Scenario of Global Rare Neurodegenerative Disease Treatment Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Allergan plc
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Bayer AG
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. GlaxoSmithKline plc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Johnson & Johnson Services Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Merck & Co. Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Rare Neurodegenerative Disease Treatment Market by Indications
4.1.1. Parkinson's Disease
4.1.2. Amyotrophic Lateral Sclerosis
4.1.3. Alzheimer’s Disease
4.1.4. Multiple Sclerosis
4.1.5. Spinal Muscular Atrophy (SMA)
4.1.6. Huntington Disease
4.1.7. Other Indications
4.2. Global Rare Neurodegenerative Disease Treatment Market by Drug class
4.2.1. Immunomodulator Drugs
4.2.2. Cholinesterase Inhibitors
4.2.3. Dopamine Agonists
4.2.4. N-methyl-D-aspartate Receptor antagonists
4.2.5. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. ACADIA Pharmaceutical Inc.
6.2. Boehringer Ingelheim International GmbH
6.3. Biogen
6.4. F. Hoffmann – La Roche Ltd.
6.5. H. Lundbeck A/S
6.6. Mitsubishi Tanabe Pharma Corp.
6.7. Novartis AG
6.8. Orion Corp.
6.9. Pfizer Inc.
6.10. Teva Pharmaceutical Industries Ltd.
6.11. UCB S.A.
6.12. IPSEN Pharma
6.13. Exicure Inc.
1. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATIONS, 2021 - 2028 ($ MILLION)
2. GLOBAL PARKINSON INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
3. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
4. GLOBAL ALZHEIMER INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
5. GLOBAL MULTIPLE SCLEROSIS INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
6. GLOBAL SMA INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
7. GLOBAL HUNTINGTON INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
8. GLOBAL OTHER INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
9. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021 - 2028 ($ MILLION)
10. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY IMMUNOMODULATOR DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
11. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY CHOLINESTERASE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
12. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY DOPAMINE AGONISTS MARKET RESEARCH AND ANALYSIS BY REGIONCHANNEL, 2021 - 2028 ($ MILLION)
13. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
14. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021 - 2028 ($ MILLION)
15. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021 - 2028 ($ MILLION)
16. NORTH AMERICAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
17. NORTH AMERICAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATIONS, 2021 - 2028 ($ MILLION)
18. NORTH AMERICAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021 - 2028 ($ MILLION)
19. EUROPEAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
20. EUROPEAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATIONS, 2021 - 2028 ($ MILLION)
21. EUROPEAN RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021 - 2028 ($ MILLION)
22. ASIA-PACIFIC RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
23. ASIA-PACIFIC RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATIONS, 2021 - 2028 ($ MILLION)
24. ASIA-PACIFIC RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021 - 2028 ($ MILLION)
25. REST OF THE WORLD RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021 - 2028 ($ MILLION)
26. REST OF THE WORLD RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY INDICATIONS, 2021 - 2028 ($ MILLION)
27. REST OF THE WORLD RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2021 - 2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET, 2021 - 2028($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET BY SEGMENT, 2021 - 2028($ MILLION)
3. RECOVERY OF GLOBAL RARE NEURODEGENERATIVE DISEASE MARKET, 2021-2028 (%)
4. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET SHARE BY INDICATIONS, 2021 VS 2028 (%)
5. GLOBAL PARKINSON INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKETSHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL ALZHEIMER INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKETSHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL MULTIPLE SCLEROSIS INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKETSHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL SMA INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKETSHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL HUNTINGTON INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL OTHER INDICATED RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKET SHARE BY DRUG CLASS, 2021 VS 2028 (%)
13. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY IMMUNOMODULATOR DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY CHOLINESTERASE INHIBITORS DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY DOPAMINE AGONISTS MARKET SHARE BY REGION, 2021 VS 2028 (%)
16. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS MARKET SHARE BY REGION, 2021 VS 2028 (%)
17. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT BY OTHERS MARKET SHARE BY REGION, 2021 VS 2028 (%)
18. GLOBAL RARE NEURODEGENERATIVE DISEASE TREATMENT MARKETSHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. US RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
20. CANADA RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
21. UK RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
22. FRANCE RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
23. GERMANY RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
24. ITALY RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
25. SPAIN RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
26. REST OF EUROPE RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
27. INDIA RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
28. CHINA RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
29. JAPAN RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
30. REST OF ASIA-PACIFIC RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
31. REST OF THE WORLD RARE NEURODEGENERATIVE DISEASE MARKETSIZE, 2021 - 2028($ MILLION)
